Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 533
Filter
1.
Histopathology ; 76(3): 411-422, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31505033

ABSTRACT

AIMS: Minor salivary gland tumours showing a predominant papillary-cystic structure are rare, and constitute a mixture of various types of neoplasm; thus, the histopathological assessment of these tumours poses a significant diagnostic challenge. We aimed to delineate the histological characteristics of these tumours and further mutational aspects with a particular focus on sialadenoma papilliferum (SP) and intraductal papillary mucinous neoplasm (IPMN). METHODS AND RESULTS: We retrieved 28 papillary-cystic tumours of the minor salivary glands, and performed histological re-evaluation and mutation analyses of several key oncogenes. The histological classifications were as follows: SP (n = 10), SP-like intraductal papillary tumour (SP-IPT) (n = 2), IPMN (n = 9), intraductal papilloma, cystadenoma, and cystadenocarcinoma (two, three and two respectively). Whereas SP typically consisted of a combination of exophytic squamous epithelium and endophytic intraductal papillary infoldings, SP-IPT lacked the exophytic component. SP and SP-IPT frequently harboured BRAF V600E mutations (75.0%), which were identified in both squamous and ductal components. IPMN was characterised by a well-demarcated cystic lesion filled exclusively with a papillary proliferation of mucinous cells and a high rate of AKT1 E17K mutations (88.9%). Intraductal papillomas were unilocular cystic lesions with intraluminal papillary growth of bland columnar cells. In contrast, both cystadenomas and cystadenocarcinomas showed a multicystic appearance with a papillary configuration. Cystadenocarcinomas invaded the surrounding tissue and were composed of markedly atypical tumour cells. CONCLUSION: The appropriate interpretation of histological findings and specific genetic alterations (e.g. BRAF V600E and AKT1 E17K in SP and IPMN) would be useful for the correct diagnosis of minor salivary gland papillary-cystic tumours.


Subject(s)
Cystadenocarcinoma/genetics , Cystadenoma/genetics , Papilloma, Intraductal/genetics , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins c-akt/genetics , Salivary Gland Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Amino Acid Substitution , Cystadenocarcinoma/classification , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/pathology , Cystadenoma/classification , Cystadenoma/diagnosis , Cystadenoma/pathology , Female , Humans , Immunohistochemistry , Male , Middle Aged , Mutation , Papilloma, Intraductal/classification , Papilloma, Intraductal/diagnosis , Papilloma, Intraductal/pathology , Salivary Gland Neoplasms/classification , Salivary Gland Neoplasms/diagnosis , Salivary Gland Neoplasms/pathology , Salivary Glands, Minor/pathology
2.
HPB (Oxford) ; 21(10): 1257-1267, 2019 10.
Article in English | MEDLINE | ID: mdl-31085104

ABSTRACT

BACKGROUND: Biliary Cystadenomas (BCA) are considered to be benign but may transform to Biliary Cystadenocarcinomas (BCAC). The aim of this systematic review was to assess the diagnostic work-up and necessity of complete surgical resection. METHOD: A systematic literature search was performed in Embase.com, Medline (Ovid), Cochrane Central, Web-of-Science and Google Scholar. Articles reporting on diagnostic work-up or outcome of various treatment strategies were included. RESULTS: Fifty-one articles with 1218 patients were included: 971 with BCA and 247 with BCAC. Patients with BCA were more often female (91% vs 63.8%, p < 0.001). On radiologic imaging BCAC more often had calcifications (p = 0.008), mural nodules (p < 0.001) and wall enhancement (p < 0.001). Reported treatment strategies were resection, enucleation, or fenestration/marsupialization. Recurrence was reported in 5.4% after resection for BCA and 4.8% after resection for BCAC. Recurrence after fenestration/marsupialization varied from 81.6% to 100% for both BCA as BCAC. Mortality rate was 0 in patients with BCA and 24% in BCAC. CONCLUSION: Due to the difficulty in accurately diagnosing these biliary cystic lesions and the availability of different surgical approaches, patients with suspected BCA or BCAC should be treated in a center specialized in liver surgery with state-of-the-art imaging and all surgical techniques to prevent mismanagement of this rare disease.


Subject(s)
Bile Duct Neoplasms/diagnosis , Bile Ducts, Intrahepatic/diagnostic imaging , Cystadenocarcinoma/diagnosis , Cystadenoma/diagnosis , Hepatectomy/methods , Magnetic Resonance Imaging/methods , Tomography, X-Ray Computed/methods , Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic/surgery , Cystadenocarcinoma/surgery , Cystadenoma/surgery , Diagnosis, Differential , Humans
3.
Khirurgiia (Mosk) ; (4): 61-65, 2019.
Article in Russian | MEDLINE | ID: mdl-31120449

ABSTRACT

Treatment of acute and chronic appendicitis is still an actual problem. There are some rare courses of the disease besides well-known complications of appendicitis. Mucocele is one of the rarest forms of chronic appendicitis. Mucocele is not accompanied by clinical symptoms and diagnosed accidentally in more than 25% of cases. The most serious complication of mucocele of the appendix is malignization observed in up to 36% of cases. Ultrasound, CT and colonoscopy are the most effective methods of perioperative diagnosis. Unclear symptoms, delayed diagnosis and surgical treatment increase the risk of complications (i.e. cystadenocarcinoma).


Subject(s)
Appendectomy/methods , Appendiceal Neoplasms/surgery , Cystadenoma, Mucinous/surgery , Appendiceal Neoplasms/diagnosis , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/surgery , Cystadenoma, Mucinous/diagnosis , Diagnosis, Differential , Humans , Laparoscopy
4.
Gan To Kagaku Ryoho ; 45(10): 1516-1518, 2018 Oct.
Article in Japanese | MEDLINE | ID: mdl-30382063

ABSTRACT

A 74-year-old woman was found to have a hepatic mass based on CT findings. She was diagnosed as having cecum cancer, and it was difficult to distinguish whether the hepatic mass was liver metastasis or biliary cystadenocarcinoma. We proceeded with the surgery for cecum cancer, and laparoscopic ileocecal resection with D3 lymph node dissection was performed. The histopathological diagnosis was mucinous adenocarcinoma, and the pathological stage was T3N2H1P0M1a, Stage IV. After the surgery, her CEA level was elevated, and we diagnosed the hepatic mass as a liver metastasis. A CapeOX plus bevacizumab regimen was administered but was discontinued for 2 courses due to the development of adverse effects and her decision. Gd-EOB-DTPA-enhanced MRI revealed a multilocular and lobulated mass, which was a low-intensity area in T1WI and high-intensity area in T2WI, and the mass had no significant contrast effects. These images were unspecific for liver metastasis of colorectal cancer, and we performed segmental 6 hepatectomy for diagnosis and curative surgery. A histopathological diagnosis of liver metastasis of cecum cancer was made. Here, we report a case of liver metastasis of colorectal cancer that was undifferentiated from biliary cystadenocarcinoma.


Subject(s)
Appendiceal Neoplasms/pathology , Bile Duct Neoplasms/diagnosis , Cystadenocarcinoma/diagnosis , Liver Neoplasms/secondary , Aged , Appendiceal Neoplasms/drug therapy , Appendiceal Neoplasms/surgery , Bile Duct Neoplasms/pathology , Colectomy , Diagnosis, Differential , Female , Hepatectomy , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery
5.
BMC Womens Health ; 16: 21, 2016 05 03.
Article in English | MEDLINE | ID: mdl-27142415

ABSTRACT

BACKGROUND: Carcinoma of the recto-vaginal septum is a quite rare location and related to peritoneal and primary ovarian carcinomas. There are only few reports in the literature with a very poor prognosis. CASE PRESENTATION: Here we report the case of a 63 years old woman with past medical history of left oophorectomy presenting with a pelvic pain. The magnetic resonance imaging (MRI) demonstrated a 10 cm mass located in the recto-vaginal septum. A block resection was performed allowing the retrieval of a 10 cm solid tumor of the recto-vaginal septum. Peritoneal biopsies and the right ovary were normal the final diagnosis was cystadenocarcinoma of the recto-vaginal septum. The patient received adjuvant chemotherapy and displays no sign of recurrence 36 months after diagnosis. CONCLUSION: The management of recto-vaginal septum carcinoma with en bloc resection should be performed to avoid peritoneal spread and improve prognosis.


Subject(s)
Cystadenocarcinoma/physiopathology , Vaginal Neoplasms/surgery , Adnexal Diseases/complications , Adnexal Diseases/etiology , Bevacizumab/pharmacology , Bevacizumab/therapeutic use , Carboplatin/pharmacology , Carboplatin/therapeutic use , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/epidemiology , Dyslipidemias/etiology , Female , Humans , Hysterectomy/methods , Middle Aged , Pain/etiology , Prognosis , Vaginal Neoplasms/physiopathology
6.
Gynecol Obstet Invest ; 81(5): 385-93, 2016.
Article in English | MEDLINE | ID: mdl-27309542

ABSTRACT

BACKGROUND/AIMS: The aim of this study was to perform a systematic review on primary retroperitoneal cystoadenocarcinoma (PRC), which is an extremely rare disease. METHODS: According to PRISMA guidelines, all the literature about PRC from 1977 to 2015 was reviewed. Thirty articles were selected; characteristics of the patients were collected and described; time to recurrence and overall survival (OS) were investigated when available. RESULTS: Thirty seven patients were included of whom 33 were females; the median age at presentation was 43. PRC was more common in postmenopausal women. Surgery was the standard therapy; the role of chemotherapy and/or radiotherapy was uncertain. Thirty percent of the patients relapsed after 58 months from the surgery; the rupture of the cyst occurred in 13% of the cases and it was associated with poor prognosis as well as premenopausal status. At 125 months from the diagnosis, 72% of the patients were alive and the median OS was not reached. CONCLUSIONS: The present systematic review about PRC is the first performed until the date of drafting this paper. We described some clinical features of PRC and their possible prognostic value. No conclusive data can be presented due to the small population analyzed and to publication bias.


Subject(s)
Cystadenocarcinoma , Retroperitoneal Neoplasms , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/epidemiology , Cystadenocarcinoma/therapy , Humans , Neoplasm Recurrence, Local , Prognosis , Retroperitoneal Neoplasms/diagnosis , Retroperitoneal Neoplasms/epidemiology , Retroperitoneal Neoplasms/therapy
7.
Ann Surg ; 261(2): 361-7, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24509187

ABSTRACT

OBJECTIVE: To characterize clinical and radiological features associated with biliary cystic tumors (BCTs) of the liver, and to define recurrence-free and overall survival. BACKGROUND: Biliary cystadenoma (BCA) and biliary cystadenocarcinoma (BCAC) are rare tumors that arise in the liver. METHODS: Between 1984 and 2013, 248 patients who underwent surgical resection of BCA or BCAC were identified. Clinical and outcome data were analyzed. RESULTS: Median total bilirubin, CA19-9, and carcinoembryonic antigen (CEA) levels were 0.6 mg/dL, 15.0 U/mL, and 2.7 ng/mL, respectively. Preoperative imaging included computed tomography only (62.5%), magnetic resonance imaging only (6.9%), or CT + MRI (18.5%). Features on cross-sectional imaging included multiloculation (56.9%), mural nodularity (16.5%), and biliary ductal dilatation (17.7%). The presence of these factors did not reliably predict BCAC versus BCA (sensitivity, 81%; specificity, 21%). Median biliary cyst size was 10.0 cm (interquartile range, 7-13 cm). Operative interventions included unroofing/partial excision of the lesion (14.1%), less than hemihepatectomy (48.8%), or hemi-/extended hepatectomy (36.3%). On pathology most lesions were BCA (89.1%), whereas 27 (10.9%) were BCAC. At last follow-up, there were 46 (18.3%) recurrences; 2 patients who initially had BCA recurred with BCAC. Median overall survival was 18.1 years; 1-year, 3-year, and 5-year survival was 95.0%, 86.8%, and 84.2%, respectively. Long-term outcomes were associated with BCAC versus BCA, as well as the presence of spindle cell/ovarian stroma (both P < 0.05). CONCLUSIONS: Among patients undergoing surgery for BCT, associated malignancy was uncommon (10%) and no preoperative findings reliably predicted underlying BCAC. After excision of BCA, long-term outcomes were good; however, patients with BCAC had a worse long-term prognosis.


Subject(s)
Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic/surgery , Cystadenocarcinoma/surgery , Cystadenoma/surgery , Hepatectomy , Adolescent , Adult , Aged , Aged, 80 and over , Bile Duct Neoplasms/diagnosis , Bile Duct Neoplasms/mortality , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/mortality , Cystadenoma/diagnosis , Cystadenoma/mortality , Databases, Factual , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Survival Analysis , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
8.
Am J Gastroenterol ; 110(6): 909-14, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25986360

ABSTRACT

OBJECTIVES: Better diagnostic tools are needed to differentiate pancreatic cyst subtypes. A previous metabolomic study showed cyst fluid glucose as a potential marker to differentiate mucinous from non-mucinous pancreatic cysts. This study seeks to validate these earlier findings using a standard laboratory glucose assay, a glucometer, and a glucose reagent strip. METHODS: Using an IRB-approved prospectively collected bio-repository, 65 pancreatic cyst fluid samples (42 mucinous and 23 non-mucinous) with histological correlation were analyzed. RESULTS: Median laboratory glucose, glucometer glucose, and percent reagent strip positive were lower in mucinous vs. non-mucinous cysts (P<0.0001 for all comparisons). Laboratory glucose<50 mg/dl had a sensitivity of 95% and a specificity of 57% (LR+ 2.19, LR- 0.08). Glucometer glucose<50 mg/dl had a sensitivity of 88% and a specificity of 78% (LR+ 4.05, LR- 0.15). Reagent strip glucose had a sensitivity of 81% and a specificity of 74% (LR+ 3.10, LR- 0.26). CEA had a sensitivity of 77% and a specificity of 83% (LR+ 4.67, LR- 0.27). The combination of having either a glucometer glucose<50 mg/dl or a CEA level>192 had a sensitivity of 100% but a low specificity of 33% (LR+ 1.50, LR- 0.00). CONCLUSIONS: Glucose, whether measured by a laboratory assay, a glucometer, or a reagent strip, is significantly lower in mucinous cysts compared with non-mucinous pancreatic cysts.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoembryonic Antigen/metabolism , Carcinoma, Pancreatic Ductal/diagnosis , Cyst Fluid/chemistry , Glucose/metabolism , Neoplasms, Cystic, Mucinous, and Serous/diagnosis , Pancreatic Cyst/diagnosis , Pancreatic Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Biopsy, Fine-Needle , Carcinoembryonic Antigen/analysis , Carcinoma, Pancreatic Ductal/metabolism , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/metabolism , Cystadenocarcinoma, Mucinous/diagnosis , Cystadenocarcinoma, Mucinous/metabolism , Female , Glucose/analysis , Humans , Male , Middle Aged , Neoplasms, Cystic, Mucinous, and Serous/metabolism , Pancreatic Cyst/metabolism , Pancreatic Neoplasms/metabolism , Pancreatic Pseudocyst/diagnosis , Pancreatic Pseudocyst/metabolism , Prospective Studies , Sensitivity and Specificity , Young Adult
9.
BMC Gastroenterol ; 15: 67, 2015 Jun 10.
Article in English | MEDLINE | ID: mdl-26058559

ABSTRACT

BACKGROUND: Intrahepatic biliary mucinous cystic neoplasms are rare hepatic tumors and account for less than 5% of intrahepatic cystic lesions. Accurate preoperative diagnosis is difficult and the outcome differs among various treatment modalities.The aim of this study is to investigate the clinico-radiological characteristics of intrahepatic biliary mucinous cystic neoplasms and to establish eligible diagnostic and treatment suggestions. METHODS: Nineteen patients with intrahepatic biliary cystadenomas and two patients with biliary cystadenocarcinomas were retrospectively reviewed. Their clinico-radiological variables and survival outcome were analyzed. RESULTS: Of the 19 patients with biliary cystadenoma, 16 (84.2 %) were female. 11 (57.9 %) patients had symptoms before operation with the most common presenting symptom being abdominal pain. Among the patients with available data, serum and cystic fluid CA 19-9 levels were invariably elevated and the CA 19-9 level in the cystic fluid was significantly higher than that in the serum. Loculations (84.2 %) and septations (63.2 %) were the most common radiologic findings. For treatment, 11 (57.9 %) patients received radical resection by either enucleation or hepatic resection, while the remaining 8 (42.1 %) patients underwent only fenestration of liver cysts. Radical resection provided a significantly better clinical outcome than fenestration in terms of tumor recurrence (p = 0.018). The only two male patients with biliary cystadenocarcinoma received radical hepatic resection and achieved a disease-free survival of 16.5 months and 33 months, respectively. CONCLUSION: Intrahepatic biliary mucinous cystic neoplasms are rare and preoperative diagnosis is difficult. Internal septations and loculations on radiologic examinations should raise some suspicion of this diagnosis. Complete tumor excision is the standard treatment that may provide patients with better long term results after the operation.


Subject(s)
Bile Duct Neoplasms/diagnosis , Bile Ducts, Intrahepatic , Cystadenocarcinoma/diagnosis , Cystadenoma/diagnosis , Hepatectomy , Adult , Aged , Aged, 80 and over , Bile Duct Neoplasms/diagnostic imaging , Bile Duct Neoplasms/mortality , Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic/diagnostic imaging , Bile Ducts, Intrahepatic/surgery , Cystadenocarcinoma/diagnostic imaging , Cystadenocarcinoma/mortality , Cystadenocarcinoma/surgery , Cystadenoma/diagnostic imaging , Cystadenoma/mortality , Cystadenoma/surgery , Female , Follow-Up Studies , Hepatectomy/methods , Humans , Male , Middle Aged , Preoperative Period , Radiography , Retrospective Studies , Survival Analysis , Treatment Outcome
10.
Methods ; 67(3): 344-53, 2014 Jun 01.
Article in English | MEDLINE | ID: mdl-24561168

ABSTRACT

In order to improve our understanding of cancer and develop multi-layered theoretical models for the underlying mechanism, it is essential to have enhanced understanding of the interactions between multiple levels of genomic data that contribute to tumor formation and progression. Although there exist recent approaches such as a graph-based framework that integrates multi-omics data including copy number alteration, methylation, gene expression, and miRNA data for cancer clinical outcome prediction, most of previous methods treat each genomic data as independent and the possible interplay between them is not explicitly incorporated to the model. However, cancer is dysregulated by multiple levels in the biological system through genomic, epigenomic, transcriptomic, and proteomic level. Thus, genomic features are likely to interact with other genomic features in the different genomic levels. In order to deepen our knowledge, it would be desirable to incorporate such inter-relationship information when integrating multi-omics data for cancer clinical outcome prediction. In this study, we propose a new graph-based framework that integrates not only multi-omics data but inter-relationship between them for better elucidating cancer clinical outcomes. In order to highlight the validity of the proposed framework, serous cystadenocarcinoma data from TCGA was adopted as a pilot task. The proposed model incorporating inter-relationship between different genomic features showed significantly improved performance compared to the model that does not consider inter-relationship when integrating multi-omics data. For the pair between miRNA and gene expression data, the model integrating miRNA, for example, gene expression, and inter-relationship between them with an AUC of 0.8476 (REI) outperformed the model combining miRNA and gene expression data with an AUC of 0.8404. Similar results were also obtained for other pairs between different levels of genomic data. Integration of different levels of data and inter-relationship between them can aid in extracting new biological knowledge by drawing an integrative conclusion from many pieces of information collected from diverse types of genomic data, eventually leading to more effective screening strategies and alternative therapies that may improve outcomes.


Subject(s)
Cystadenocarcinoma/genetics , Genomics/methods , Ovarian Neoplasms/genetics , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/therapy , Female , Gene Expression Profiling , Humans , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/therapy , Precision Medicine , Prognosis , Treatment Outcome
11.
Magy Onkol ; 59(3): 205-13, 2015 Sep.
Article in Hungarian | MEDLINE | ID: mdl-26339910

ABSTRACT

The ovary is a common site of metastases. Secondary tumors account for 3-40% of all ovarian malignancies. Most ovarian metastases arise from the colon, although tumors of the breast, stomach and endometrium are also common places of origin. Clinical and histological features of metastatic tumors frequently mimic primary ovarian malignancies, causing serious diagnostic problems for the surgical pathologist. However, differentiation between primary ovarian cancer and ovarian metastasis is important in order to prevent inappropriate management and suboptimal treatment. The distinction between primary and secondary ovarian malignancies is especially difficult in cases when the metastasis is diagnosed before the primary tumor. Frozen section is widely used in the intra-operative assessment of patients with ovarian tumors but it can be very difficult to distinguish certain types of primary ovarian tumors and metastases from other sites. We examined 152 cases of secondary ovarian neoplasm diagnosed at the National Institute of Oncology, Hungary from 2000 to 2014. Colorectal cancer was the most common primary tumor (58 cases), followed by breast (33 cases), endometrium (30 cases) and stomach cancer (13 cases). The differential diagnosis proved the most difficult in cases when endometrioid and mucinous tumors were present in the ovaries. Metastases of colorectal and gastric adenocarcinomas may simulate benign or borderline cystadenomas too. In these cases the knowledge of the patient's history and immunohistochemical stains were helpful. In our study we discuss the diagnostic challenge of distinguishing these secondary ovarian tumors from primary ovarian neoplasms and the limits of the intraoperative frozen sections.


Subject(s)
Adenocarcinoma/diagnosis , Adenocarcinoma/secondary , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/secondary , Adenocarcinoma/genetics , Adult , Aged , Breast Neoplasms/epidemiology , Breast Neoplasms/pathology , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/pathology , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/secondary , Cystadenocarcinoma, Mucinous/diagnosis , Cystadenocarcinoma, Mucinous/secondary , Diagnosis, Differential , Endometrial Neoplasms/epidemiology , Endometrial Neoplasms/pathology , Female , Frozen Sections , Humans , Hungary/epidemiology , Immunohistochemistry , Middle Aged , Ovarian Neoplasms/genetics , Stomach Neoplasms/epidemiology , Stomach Neoplasms/pathology
12.
Mod Pathol ; 27(1): 30-7, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23807775

ABSTRACT

Mammary analog secretory carcinoma of salivary gland is a recently described entity with unique morphologic, clinical, and genetic characteristics, including the characteristic t(12;15)(p13;q25) with ETV6-NTRK3 translocation found in secretory carcinomas of the breast. Before their initial description, these salivary gland tumors were generally diagnosed as acinic cell carcinoma or adenocarcinoma. For the purpose of this study, all cases of salivary gland acinic cell carcinoma, cribriform cystadenocarcinoma, and adenocarcinoma, not otherwise specified (NOS), diagnosed over a 10-year period were retrieved from our surgical pathology files. There were a total of 11 cases diagnosed as acinic cell carcinoma, 10 cases of adenocarcinoma, NOS, and 6 cases of cribriform cystadenocarcinoma. All slides were reviewed by two pathologists (AP, CGF) and tumors that show morphologic features of mammary analog secretory carcinoma according to the recent literature were selected. This process narrowed down the initial number to six cases originally diagnosed as acinic cell carcinoma, three cases originally diagnosed as adenocarcinoma, NOS, and one case originally diagnosed as cribriform cystadenocarcinoma. The 10 cases were subjected to immunohistochemistry for S-100, mammaglobin, and ANO1, as well as fluorescence in situ hybridization analysis for t(12;15)(p13;q25) with ETV6-NTRK3 fusion rearrangement. The ETV6-NTRK3 gene rearrangement was detected in three tumors. These three tumors, initially diagnosed as acinic cell carcinomas, stained positive for S-100 and mammaglobin, and negative for ANO1 by immunohistochemistry. Two of the three patients were male (2/3). In summary, mammary analog secretory carcinoma is a newly described diagnostic entity that should be in the differential diagnosis of salivary gland tumors that morphologically mimic other neoplasms, mainly acinic cell carcinomas. They differ from conventional acinic cell tumors immunohistochemically and molecularly. Positivity for mammaglobin and S-100, and negativity for ANO1 are useful screening tools before confirmatory molecular studies.


Subject(s)
Breast Neoplasms/diagnosis , Carcinoma, Acinar Cell/diagnosis , Carcinoma/diagnosis , Cystadenocarcinoma/diagnosis , Salivary Gland Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Anoctamin-1 , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Biopsy , Breast Neoplasms/chemistry , Breast Neoplasms/classification , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Carcinoma/chemistry , Carcinoma/classification , Carcinoma/genetics , Carcinoma/pathology , Carcinoma, Acinar Cell/chemistry , Carcinoma, Acinar Cell/classification , Carcinoma, Acinar Cell/genetics , Carcinoma, Acinar Cell/pathology , Chloride Channels/analysis , Chromosomes, Human, Pair 12 , Chromosomes, Human, Pair 15 , Cystadenocarcinoma/chemistry , Cystadenocarcinoma/classification , Cystadenocarcinoma/genetics , Cystadenocarcinoma/pathology , Diagnosis, Differential , Female , Gene Rearrangement , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Male , Middle Aged , Neoplasm Proteins/analysis , Oncogene Proteins, Fusion/genetics , Predictive Value of Tests , S100 Proteins/analysis , Salivary Gland Neoplasms/chemistry , Salivary Gland Neoplasms/classification , Salivary Gland Neoplasms/genetics , Salivary Gland Neoplasms/pathology , Secretoglobins/analysis , Translocation, Genetic
13.
BMC Gastroenterol ; 14: 109, 2014 Jun 16.
Article in English | MEDLINE | ID: mdl-24934314

ABSTRACT

BACKGROUND: Hepatobiliary cystadenocarcinoma is a rare epithelial malignant neoplasm of the liver or extrahepatic bile ducts. Early diagnosis of hepatobiliary cystadenocarcinoma is difficult because of its asymptomatic features and rarity. Moreover, the molecular pathogenesis of hepatobiliary cystadenocarcinoma remains unclear. Herein, we described a case of hepatobiliary cystadenocarcinoma in female with chronic hepatitis B and repeated hepatolithiasis. CASE PRESENTATION: A 65-year-old woman with medical history of latent hepatitis B virus infection, repeated choledocholisthiasis, and cholecystitis was admitted due to a heterogeneous cystic mass (5.6 cm × 4 cm) shown on abdominal ultrasonography during regular physical checkup. The patient complained about irregular bowel movements with intermittent diarrhea for two months before presentation. Computed tomography (CT) disclosed a multiloculated cystic lesion in the left hepatic lobe with the presence of intraductal stones and dilatation of intrahepatic ducts. Histological results obtained from left lobectomy specimens showed hepatobiliary cystadenocarcinoma without accompanied mesenchymal stroma. CONCLUSION: Notably, hepatobiliary cystadenocarcinoma without mesenchymal stroma seldom occurs in women and is usually associated with poor prognosis. We present the rare findings in this patient and suggest that chronic inflammatory insults in the intrahepatic bile ducts might shed light on the cystadenocarcinogenesis.


Subject(s)
Bile Duct Neoplasms/diagnosis , Bile Ducts, Intrahepatic , Cystadenocarcinoma/diagnosis , Aged , Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic/diagnostic imaging , Bile Ducts, Intrahepatic/pathology , Cystadenocarcinoma/surgery , Female , Humans , Tomography, X-Ray Computed , Ultrasonography
14.
Gastrointest Endosc ; 78(2): 295-302.e2, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23566642

ABSTRACT

BACKGROUND: Better pancreatic cyst fluid biomarkers are needed. OBJECTIVE: To determine whether metabolomic profiling of pancreatic cyst fluid would yield clinically useful cyst fluid biomarkers. DESIGN: Retrospective study. SETTING: Tertiary-care referral center. PATIENTS: Two independent cohorts of patients (n = 26 and n = 19) with histologically defined pancreatic cysts. INTERVENTION: Exploratory analysis for differentially expressed metabolites between (1) nonmucinous and mucinous cysts and (2) malignant and premalignant cysts was performed in the first cohort. With the second cohort, a validation analysis of promising identified metabolites was performed. MAIN OUTCOME MEASUREMENTS: Identification of differentially expressed metabolites between clinically relevant cyst categories and their diagnostic performance (receiver operating characteristic [ROC] curve). RESULTS: Two metabolites had diagnostic significance-glucose and kynurenine. Metabolomic abundances for both were significantly lower in mucinous cysts compared with nonmucinous cysts in both cohorts (glucose first cohort P = .002, validation P = .006; and kynurenine first cohort P = .002, validation P = .002). The ROC curve for glucose was 0.92 (95% confidence interval [CI], 0.81-1.00) and 0.88 (95% CI, 0.72-1.00) in the first and validation cohorts, respectively. The ROC for kynurenine was 0.94 (95% CI, 0.81-1.00) and 0.92 (95% CI, 0.76-1.00) in the first and validation cohorts, respectively. Neither could differentiate premalignant from malignant cysts. Glucose and kynurenine levels were significantly elevated for serous cystadenomas in both cohorts. LIMITATIONS: Small sample sizes. CONCLUSION: Metabolomic profiling identified glucose and kynurenine to have potential clinical utility for differentiating mucinous from nonmucinous pancreatic cysts. These markers also may diagnose serous cystadenomas.


Subject(s)
Biomarkers, Tumor/metabolism , Cyst Fluid/metabolism , Cystadenocarcinoma/metabolism , Cystadenoma/metabolism , Glucose/metabolism , Kynurenine/metabolism , Pancreatic Cyst/metabolism , Pancreatic Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma, Pancreatic Ductal/diagnosis , Carcinoma, Pancreatic Ductal/metabolism , Cohort Studies , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma, Mucinous/diagnosis , Cystadenocarcinoma, Mucinous/metabolism , Cystadenoma/diagnosis , Cystadenoma, Mucinous/diagnosis , Cystadenoma, Mucinous/metabolism , Cystadenoma, Serous/diagnosis , Cystadenoma, Serous/metabolism , Female , Humans , Male , Metabolomics , Middle Aged , Pancreatic Cyst/diagnosis , Pancreatic Neoplasms/diagnosis , Pancreatic Pseudocyst/diagnosis , Pancreatic Pseudocyst/metabolism , Retrospective Studies , Sensitivity and Specificity
15.
Hepatobiliary Pancreat Dis Int ; 12(3): 329-31, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23742780

ABSTRACT

BACKGROUND: Hepatobiliary cystadenocarcinoma represents a rare epithelial malignant tumor derived from the intrahepatic bile duct. METHODS: A 71-year-old woman, who had undergone laparoscopic drainage of a cystic lesion of the right hepatic lobe, was misdiagnosed as having hepatic echinococcal disease, and received intracystic infusion of 95% ethanol four years ago. She was admitted to our hospital for further treatment. RESULTS: Physical examination revealed dilated superficial veins across the right abdominal wall. After mapping the direction of blood flow in these vessels, we assumed that this was a sign of inferior vena cava obstruction. Abdominal ultrasound, computed tomography, magnetic resonance imaging combined with magnetic resonance angiography showed a large cystic mass in the right upper quadrant and epigastrium, displacing the adjacent structures, adherent to the inferior vena cava, which was not patent, resulting in dilation of superficial epigastric veins. The patient underwent an exploratory laparotomy. Total excision of the huge mass measuring 16X15 cm was possible under selective vascular exclusion of the liver. Removal of the tumor resulted in immediate restoration of flow in the inferior vena cava. On the basis of the pathology and findings of immunohistochemical analysis, a hepatobiliary cystadenocarcinoma was diagnosed. CONCLUSIONS: In the present case, hepatobiliary cystadenocarcinoma was accompanied by dilated superficial venous collaterals due to inferior vena cava obstruction. Selective vascular exclusion of the liver allowed a safe oncological resection of the tumor.


Subject(s)
Bile Duct Neoplasms/complications , Bile Ducts, Intrahepatic , Collateral Circulation , Cystadenocarcinoma/complications , Liver Circulation , Vascular Diseases/etiology , Vena Cava, Inferior/physiopathology , Aged , Bile Duct Neoplasms/diagnosis , Bile Duct Neoplasms/physiopathology , Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic/pathology , Bile Ducts, Intrahepatic/surgery , Biopsy , Constriction, Pathologic , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/physiopathology , Cystadenocarcinoma/surgery , Diagnostic Errors , Echinococcosis, Hepatic/diagnosis , Echinococcosis, Hepatic/therapy , Ethanol/administration & dosage , Female , Humans , Magnetic Resonance Angiography , Phlebography/methods , Predictive Value of Tests , Recovery of Function , Tomography, X-Ray Computed , Treatment Outcome , Vascular Diseases/diagnosis , Vascular Diseases/physiopathology , Vena Cava, Inferior/pathology
16.
Dermatol Online J ; 19(9): 19620, 2013 Sep 14.
Article in English | MEDLINE | ID: mdl-24050294

ABSTRACT

Syringocystadenocarcinoma papilliferum (SCACP) is a rare adenexal carcinoma with only 21 cases reported in the literature. Most patients describe a long-standing mass with recent change, supporting the idea that SCACP arises from malignant transformation of pre-existing syringocystadenoma papilliferum (SCAP). Syringocystadenocarcinoma papilliferum is generally treated with wide surgical excision of the lesion and patients do exceeding well and require no systemic therapy.


Subject(s)
Cystadenocarcinoma/diagnosis , Head and Neck Neoplasms/diagnosis , Scalp/pathology , Sweat Gland Neoplasms/diagnosis , Adenoma, Sweat Gland/congenital , Adenoma, Sweat Gland/pathology , Aged , Cystadenocarcinoma/pathology , Cystadenocarcinoma/surgery , Disease Progression , Head and Neck Neoplasms/congenital , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/surgery , Humans , Male , Sweat Gland Neoplasms/congenital , Sweat Gland Neoplasms/pathology , Sweat Gland Neoplasms/surgery
17.
Clin Radiol ; 67(8): 727-37, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22520033

ABSTRACT

Cystic pancreatic neoplasms are often an incidental finding, the frequency of which is increasing. The understanding of such lesions has increased in recent years, but the numerous types of lesions involved can hinder differential diagnosis. They include, in particular, intraductal papillary mucinous neoplasms (IPMN), serous cystic neoplasms (SCN), and mucinous cystic neoplasms (MCN). Knowledge of their histological and radiological structure, as well as distribution in terms of localization, age, and sex, helps to differentiate such tumours from common pancreatic pseudocysts. Several types of cystic pancreatic neoplasms can undergo malignant transformation and, therefore, require differentiated radiological management. This review aims to develop a broader understanding of the pathological and radiological characteristics of cystic pancreatic neoplasms, and provide a guideline for everyday practice based on current concepts in the radiological management of the given lesions.


Subject(s)
Cystadenocarcinoma/diagnosis , Pancreatic Neoplasms/diagnosis , Age Factors , Cystadenocarcinoma/pathology , Diagnosis, Differential , Female , Humans , Incidental Findings , Magnetic Resonance Imaging , Male , Multidetector Computed Tomography , Pancreatic Neoplasms/pathology , Pancreatic Pseudocyst/diagnosis , Sex Factors
18.
Pathol Int ; 62(7): 506-10, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22726072

ABSTRACT

A 40-year-old Japanese man was admitted to our hospital for evaluation of upper abdominal pain. Abdominal computed tomography (CT) revealed a well-circumscribed multicystic mass measuring approximately 7 × 6 cm. The mass contained a solid lesion measuring 3 × 2 cm. Biopsy of a swollen cervical lymph node led to a diagnosis of diffuse large B-cell lymphoma. After initial chemotherapy for lymphoma, the multicystic mass was surgically resected. The tumor was composed of a multicystic lesion and a solid lesion. Histopathologic examination of the multicystic lesion revealed that the locules were lined by biliary epithelium, demonstrating various degrees of cytological atypia. The stroma was fibrous, and the tumor showed marked apocrine snouts. Part of the tumor showed papillary growth with strong cytological atypia. The solid lesion showed tubulocystic proliferation of tumor cells, with prominent apocrine snouts, embedded in dense and partially hyalinized fibrous stroma. The morphology of the solid part was quite similar to that of reported biliary adenofibroma. Despite lengthy discussion, an appropriate pathological diagnosis could not be found among the current classifications of biliary tumor. The tumor was finally diagnosed as unclassified multicystic biliary tumor with adenofibroma features.


Subject(s)
Adenofibroma/diagnosis , Bile Duct Neoplasms/diagnosis , Bile Ducts, Intrahepatic/pathology , Cystadenocarcinoma/diagnosis , Lymphoma, Large B-Cell, Diffuse/diagnosis , Adenofibroma/metabolism , Adenofibroma/therapy , Adult , Bile Duct Neoplasms/metabolism , Bile Duct Neoplasms/therapy , Bile Ducts, Intrahepatic/metabolism , Combined Modality Therapy , Cystadenocarcinoma/metabolism , Cystadenocarcinoma/therapy , Diagnosis, Differential , Fatal Outcome , Humans , Keratins/metabolism , Lymph Nodes/pathology , Lymphoma, Large B-Cell, Diffuse/metabolism , Lymphoma, Large B-Cell, Diffuse/therapy , Male , Neoplasms, Multiple Primary
19.
Clin Hemorheol Microcirc ; 82(1): 95-105, 2022.
Article in English | MEDLINE | ID: mdl-35662112

ABSTRACT

Biliary cystadenocarcinoma (BCAC) is an extremely rare intrahepatic cystic tumor. Patients usually present with nonspecific symptoms such as abdominal pain, abdominal distention, and abdominal mass. This tumor occurs most commonly in the left hemiliver and is thought to mainly develop from a benign biliary cystadenoma (BCA). At present, the disease is mainly diagnosed by ultrasound, CT, MR, and other imaging methods, and the main treatment is radical surgical resection. We reported a 75-year-old female with an unresectable huge BCAC (i.e., 161×145×122 mm in three orthogonal directions) and poor general condition (40 in Karnofsky Performance Status, KPS) who received sequential thermal ablation (i.e., cryoablation and microwave ablation) in combination with sclerotherapy using lauromacrogol. The diagnosis of intrahepatic BCAC was confirmed pathologically. Preablation grayscale US showed the BCAC with a clear boundary, regular shape, and cystic-solid mixed echogenicity, which appeared as a huge multilocular cystic lesions with thick internal sepatations. Preablation contrast-enhanced ultrasound (CEUS) showed honeycomb-like hyper-enhancement of the thick internal sepatations and cystic wall in the arterial and portal phase, and sustained enhancement of the thick internal sepatations and cystic wall in the late phase. 6-month postablation CEUS showed non-enhancement in most parts of the lesion in the arterial phase and 6-month postablation MRI showed the volume reduction ratio (VRR) was about 70%. The abdominal pain and abdominal distension were relieved remarkably, and her quality of life was greatly improved (70 in KPS). In conclusion, sequential thermal ablation in combination with sclerotherapy provides a successful translative therapy for this unresectable huge BCAC with a poor general condition, which makes subsequent curative surgery or ablation possible.


Subject(s)
Cystadenocarcinoma , Cystadenoma , Abdominal Pain , Aged , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/pathology , Cystadenocarcinoma/surgery , Cystadenoma/diagnosis , Cystadenoma/pathology , Cystadenoma/surgery , Female , Humans , Polidocanol , Quality of Life , Sclerotherapy , Ultrasonography
20.
J Vet Med Sci ; 84(11): 1514-1519, 2022 Nov 07.
Article in English | MEDLINE | ID: mdl-36198612

ABSTRACT

A 14-year-old spayed female Shih-Tzu was referred to the Veterinary Medical Teaching Hospital of Konkuk University for evaluation of an abdominal mass. In diagnostic imaging, two large cystic masses were identified. The affected liver lobes were surgically resected, and the specimens were submitted for histopathological evaluation and immunohistochemical staining. The two cystic lesions were diagnosed as biliary cystadenocarcinoma (BCAC). Recurrence and regional invasion were identified on ultrasonography 36 days postoperatively. The patient died on postoperative day 271. To the best of our knowledge, previously reported case studies of BCAC in dogs presented limited clinical information. In this report, we present a detailed picture comprising a range of clinical information and histopathological examination of BCAC in a dog.


Subject(s)
Bile Duct Neoplasms , Cholangiocarcinoma , Cystadenocarcinoma , Cystadenoma , Dog Diseases , Animals , Dogs , Female , Bile Duct Neoplasms/diagnostic imaging , Bile Duct Neoplasms/surgery , Bile Duct Neoplasms/veterinary , Bile Ducts, Intrahepatic/pathology , Cholangiocarcinoma/pathology , Cholangiocarcinoma/veterinary , Cystadenocarcinoma/diagnosis , Cystadenocarcinoma/surgery , Cystadenocarcinoma/veterinary , Cystadenoma/diagnosis , Cystadenoma/pathology , Cystadenoma/surgery , Cystadenoma/veterinary , Dog Diseases/diagnostic imaging , Dog Diseases/surgery
SELECTION OF CITATIONS
SEARCH DETAIL